More than 6 million patients with heart failure are primarily managed by cardiologists in the US today, and both the incidence and prevalence are rising rapidly. Until recently, besides optimizing medical therapies, there were few unique alternatives for treating patients in the early stages of heart failure.

Now breakthrough device therapies have changed everything for a large majority of NYHA Class III patients. As such, it has never been more important to carefully and accurately assess a given patient's NYHA class. From now on, Don't Guess – Assess.

Accurately discriminating between NYHA class II and III is now as or more important than accurately assessing ejection fraction to prescribe an ICD for prevention of sudden cardiac death. With the advent of cardiac contractility modulation therapy, "Hope is Here" for you and your patients who previously had no option except to manage through progressively worsening symptoms to the point of LVAD or transplant.

CCM® can be provided early on - within a wider EF range between 25% and 45% - to enhance quality of life while maintaining or improving NYHA functional status for NYHA Class III patients.

Learn more . . .